Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DANYELZA vs POTELIGEO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.
Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).
Neuroblastoma: in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and retinoic acid for treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.
Adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy
1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.
3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.
Terminal elimination half-life is approximately 29 days (range 25–35 days) at steady state, supporting a weekly dosing schedule for maintaining therapeutic concentrations.
Terminal elimination half-life is approximately 17 days (range 11–22 days) at steady state, supporting every-2-week or every-4-week dosing intervals.
Metabolized via catabolic pathways into small peptides and amino acids; no major CYP450 involvement.
Mogamulizumab is a monoclonal antibody; metabolism is via catabolic pathways into small peptides and amino acids. No specific metabolic enzymes identified.
Renal elimination accounts for approximately 80% of the administered dose as unchanged drug; the remaining 20% is excreted via the biliary/fecal route.
POTELIGEO (mogamulizumab) is a monoclonal antibody, primarily eliminated via intracellular catabolism into amino acids. No quantitative data on renal or biliary excretion; minimal to no excretion as intact antibody in urine or feces.
Approximately 99% bound to plasma proteins, primarily albumin and low-density lipoproteins.
Approximately 95% bound to plasma proteins, predominantly to immunoglobulins and albumin as a therapeutic monoclonal antibody.
Volume of distribution is approximately 0.2 L/kg, indicating limited extravascular distribution and confinement primarily to the plasma compartment.
Volume of distribution at steady state (Vss) is approximately 5.1 L (range 3.8–6.7 L), indicative of limited extravascular distribution, consistent with a monoclonal antibody primarily confined to vascular and interstitial spaces.
Only available as intravenous formulation; bioavailability is 100% by definition for IV administration, with no oral or other route available.
Only intravenous administration; intravenous bioavailability is 100% by definition.
No dose adjustment recommended for mild to moderate renal impairment. Severe renal impairment or end-stage renal disease: not studied, use with caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Severe hepatic impairment (Child-Pugh C): not studied, use with caution.
No dose adjustment required for Child-Pugh A or B. Insufficient data for Child-Pugh C. Use with caution.
Safety and efficacy not established in pediatric patients.
Safety and effectiveness not established in pediatric patients.
No specific dose adjustment recommended; monitor for toxicity due to potential age-related renal or hepatic impairment.
No specific dose adjustment recommended. Monitor for adverse effects more frequently due to potential age-related renal and hepatic function decline.
WARNING: SERIOUS INFUSION-RELATED REACTIONS AND NEUROTOXICITY. Premedicate for infusion-related reactions. Monitor for and manage neurotoxicity (severe neuropathic pain, transverse myelitis, posterior reversible encephalopathy syndrome).
WARNING: DERMATOLOGIC TOXICITY. Severe, including fatal, dermatologic adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred. Discontinue for suspected severe cutaneous adverse reactions.
Infusion-related reactions (hypotension, urticaria, bronchospasm); neurotoxicity (severe pain, transverse myelitis, PRES); myelosuppression; capillary leak syndrome; infections; electrolyte abnormalities; fever; hypersensitivity reactions; interference with tumor response assessment.
Infusion reactions: Monitor during infusion; interrupt or discontinue based on severity.,Dermatologic toxicity: Severe skin reactions including SJS/TEN; discontinue if suspected.,Immune-mediated adverse reactions: including pneumonitis, hepatitis, colitis, endocrinopathies, and others.,Infections: Fatal infections occurred; monitor for infections and treat promptly.,Autoimmune hemolytic anemia: Fatal cases reported.,Posterior reversible encephalopathy syndrome (PRES): Discontinue if suspected.,Hematologic toxicity: Monitor blood counts; severe neutropenia, thrombocytopenia, and anemia reported.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
None known.
None
No specific food interactions are established for DANYELZA. Maintain adequate hydration and nutrition as tolerated. Avoid grapefruit and grapefruit juice if taking concomitant medications that are CYP3A4 substrates, though DANYELZA itself is not metabolized by CYP450 enzymes.
No known food interactions. Grapefruit or other CYP inhibitors/inducers are not expected to affect mogamulizumab as it is a monoclonal antibody cleared via proteolysis. No dietary restrictions necessary.
Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal toxicity including malformations and growth retardation. Advise females of reproductive potential of the potential risk to a fetus. Use effective contraception during treatment and for at least 2 months after the last dose.
POTELIGEO (mogamulizumab) is a monoclonal antibody. Ig G antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on its mechanism of action (CCR4-directed cytolytic activity), there is potential for fetal harm, including depletion of maternal and fetal T-cell subsets, especially regulatory T cells, which are critical for immune tolerance. Animal studies have not been conducted, but given the pharmacodynamics, use during pregnancy should be avoided unless clearly necessary. First trimester exposure carries theoretical risks of altered immune development; second and third trimester exposure may cause fetal lymphopenia and increased infection risk.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 2 months after the last dose.
It is unknown whether mogamulizumab is excreted in human milk. Human Ig G is present in breast milk, but concentrations are generally low. The M/P ratio has not been determined. Due to the potential for serious adverse reactions in the breastfed infant (e.g., immunosuppression), women should not breastfeed during treatment and for at least 5 half-lives (approximately 5 weeks) after the last dose.
Dosing adjustments during pregnancy are not established. Use only if potential benefit justifies potential risk to the fetus. Consider delaying treatment until after delivery if feasible.
No pharmacokinetic studies in pregnancy. Dosing adjustments are not established; however, physiologic changes in pregnancy (e.g., increased plasma volume, altered clearance) may affect pharmacokinetics. Given the monoclonal antibody, no dose adjustment is recommended, but clinical monitoring for efficacy and toxicity should be considered. Use only if potential benefit justifies potential risk.
DANYELZA (naxitamab) is a GD2-binding monoclonal antibody for relapsed/refractory high-risk neuroblastoma. Premedicate with antihistamines, acetaminophen, and corticosteroids to mitigate infusion-related reactions. Monitor for severe pain, which is a known adverse effect; may require opioid analgesics. Closely monitor for hypotension and bronchospasm during infusion. Administer in a setting equipped to manage anaphylaxis.
Poteligeo (mogamulizumab) is a humanized anti-CCR4 monoclonal antibody used for adult T-cell leukemia-lymphoma (ATLL) and mycosis fungoides (MF)/Sézary syndrome (SS). It depletes CCR4-expressing T cells, including regulatory T cells (Tregs), which may exacerbate graft-versus-host disease (GVHD) after transplant. Monitor for infusion reactions and severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome). Dose reduction for creatinine clearance <30 m L/min is not established; avoid in severe renal impairment. Premedicate with antihistamines and acetaminophen. Live vaccines contraindicated during and after treatment.
DANYELZA is given intravenously over several hours, typically on consecutive days.,You may experience severe pain during or after infusion; report it immediately.,Common side effects include fever, nausea, vomiting, and low blood pressure.,Serious allergic reactions can occur; inform your doctor if you develop hives, trouble breathing, or swelling.,Avoid driving or operating machinery if you feel dizzy or tired after treatment.,Notify your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.
Poteligeo can cause severe skin reactions; report any rash, blisters, or peeling skin immediately.,You may experience infusion reactions (fever, chills, nausea) during or after infusion; premedication will be given.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for at least 1 year after last dose.,Do not breastfeed while on Poteligeo and for at least 2 months after last dose.,Use effective birth control during treatment and for at least 3 months after last dose.,Notify your doctor if you have a history of organ transplant or are planning a transplant.,Poteligeo can lower your immune system; report signs of infection (fever, cough, sore throat).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DANYELZA vs POTELIGEO, answered by our medical review team.
DANYELZA is a Monoclonal Antibody Antineoplastic that works by Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.. POTELIGEO is a Monoclonal Antibody Antineoplastic that works by Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DANYELZA and POTELIGEO depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DANYELZA is: 1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.. The standard adult dose of POTELIGEO is: 3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DANYELZA and POTELIGEO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DANYELZA is classified as Category C. Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal. POTELIGEO is classified as Category C. POTELIGEO (mogamulizumab) is a monoclonal antibody. IgG antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on it. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.